Article
Virology
Chia-Min Wu, Fu-Hsiung Su, Chih-Hsin Muo, Jou-Chen Huang, Meei-Maan Wu, Chih-Ching Yeh
Summary: This study found that patients with HCV infection treated with PegIFN/RBV therapy had a significantly increased risk of retinopathy, particularly retinal hemorrhage.
Article
Medicine, General & Internal
Yu Liu, Hui Chen, Zhi-Ying Xu
Summary: This is a case of a patient who developed ischemic colitis during pegylated interferon-alpha (PEG-IFN-alpha) therapy. The patient presented with acute lower abdominal pain and haematochezia while receiving PEG-IFN-alpha monotherapy for chronic hepatitis B. Diagnosis was confirmed through colonoscopy and biopsies, and treatment involved discontinuation of PEG-IFN-alpha and symptomatic management. The patient recovered and subsequent colonoscopy showed normal findings.
Review
Virology
Yi-Wen Huang, Albert Qin, Chan-Yen Tsai, Pei-Jer Chen
Summary: Ropeginterferon alfa-2b is a promising treatment option for MPN and chronic viral hepatitis due to its favorable pharmacokinetic profile and demonstrated efficacy in clinical studies. Administered once every two weeks, it has shown to be well-tolerated and effective in treating chronic hepatitis B, C, and D.
Article
Pharmacology & Pharmacy
Ming-Han Hsieh, Tzu-Yu Kao, Ting-Hui Hsieh, Chun-Chi Kao, Cheng-Yuan Peng, Hsueh-Chou Lai, Po-Heng Chuang, Jung-Ta Kao
Summary: SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F >= 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2022)
Article
Chemistry, Multidisciplinary
Hafiza Rida Farooq Chudhary, Amjad Ali, Sadia Bibi, Muhammad Waqas, Shazia Rafique, Muhammad Idrees, Sobia Ahsan Halim, Magda H. Abdellattif, Ajmal Khan, Ahmed Al-Harrasi
Summary: HCV is a global public health problem with a high number of infections worldwide. It is a leading cause of liver cancer due to the frequent occurrence of HCV infection, especially in those with HCV cirrhosis. This study analyzed the transcriptional analysis of the TP53 gene in HCV-infected patients treated with different antiviral therapies. The results showed that TP53 expression was significantly upregulated in patients with virological responses and HCC, and sofosbuvir + daclatasvir treatment had a significant impact on TP53 expression.
Article
Virology
Ahmed M. Mostafa, Hesham A. Saafan, Ahmed S. Al-Tawashi, Muhannad H. Kasem, Ahmed M. Alaa, Mahmoud M. Eltobgy, Ahmed S. Moubarak, Manar M. Gharib, Mohamed A. Awwad, Hazem M. Omar, Marwa O. El-Derany
Summary: This study aimed to investigate the association between haplotypes in IL-17A receptor rs2275913 and rs3819024 and development of HCC in CHC patients treated with either triple therapy or with dual therapy. The results showed that the presence of G-G haplotype in IL-17A was inversely associated with HCC development in patients receiving triple therapy. High serum AFP levels were directly associated with HCC development in patients receiving triple therapy.
Review
Immunology
Mamun Al-Mahtab, Sheikh Mohammad Fazle Akbar, Osamu Yoshida, Julio Cesar Aguilar, Gerardo Guillen, Yoichi Hiasa
Summary: An open-level clinical trial has shown that a therapeutic vaccine, NASVAC, containing HBsAg and HBcAg, is effective and safer than Peg-IFN in treating CHB patients. The study also suggests that NASVAC may be particularly beneficial for patients with HBV genotype-D.
Article
Virology
Mengqi Luo, Lingyan Zhang, Chou Yang, Bin Zhou, Jinlin Hou, De-Ke Jiang
Summary: This study found that single-nucleotide polymorphism CXCL13_rs76084459 is significantly associated with response to PegIFNa therapy in patients with chronic hepatitis B. Furthermore, a polygenic score composed of 6 SNPs including CXCL13_rs76084459 has a better predictive value for PegIFNa treatment response.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Pharmacology & Pharmacy
Jia Hou, Chao Dong, Jiaxuan Chen, Haitao Chen, Rong Na, Bin Zhou, Jinlin Hou, De-Ke Jiang
Summary: ZHX2 and PGS have the potential to predict the response to PegIFN alpha treatment in HBeAg-positive CHB patients.
ANTIVIRAL RESEARCH
(2023)
Review
Gastroenterology & Hepatology
Lisa Sandmann, Heiner Wedemeyer
Summary: Interferon-alfa has been the main treatment for hepatitis D virus (HDV) infection, but only a portion of patients benefit from it. Successful interferon treatment is associated with improved long-term clinical outcomes. Although alternative treatments are being developed, pegylated interferon-alfa still plays an important role. There is a need for better biomarkers to select patients who are likely to benefit from interferon-based treatments.
LIVER INTERNATIONAL
(2023)
Article
Pediatrics
Yi He, Yingzhi Zhou, Huimin Wang, Xiaorong Peng, Yunan Chang, Peng Hu, Hong Ren, Hongmei Xu
Summary: This study compared the efficacy and safety of peg-IFN alpha-2a and ETV in children and adolescents with CHB. The results showed that peg-IFN was superior in achieving HBsAg and HBeAg serological response. Higher IL-18 levels were associated with HBeAg serological response.
Article
Multidisciplinary Sciences
Rashmi Rashmi, Sanjay K. Mohanty
Summary: In low-and-middle-income countries, people develop chronic diseases at a younger age, leading to health-and-economic loss. The present study aims to explore the onset of seven chronic diseases across adults and the elderly, along with the prognostic factors of chronic disease onset. The results showed a higher risk of early onset of the seven chronic diseases, especially in individuals aged 45-54 and 55-64.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Batbold Batsaikhan, Ching-I. Huang, Ming-Lun Yeh, Chung-Feng Huang, Yi-Hung Lin, Po-Cheng Liang, Ming-Yen Hsieh, Yi-Ching Lin, Jee-Fu Huang, Wan-Long Chuang, Jin-Ching Lee, Ming-Lung Yu, Hsing-Tao Kuo, Chia-Yen Dai
Summary: This study found that the prevalence of persistent cryoglobulinemia is 34.5% after completing antiviral therapy. Persistent cryoglobulinemia is associated with advanced fibrosis and HCV clearance.
Article
Public, Environmental & Occupational Health
Yadong Wang, Yangyang Hu, Xing Zhang, Yue Luo, Luyuan Ma, Jingjing Lu, Qianfei Liang, Chengjun Xu, Caiyan Zhao, Calvin Q. Pan
Summary: This study investigated the relationship between IP-10 and treatment response in patients with CHC treated with direct-acting antiviral agents. The results showed that IP-10 levels decreased gradually during the treatment and baseline IP-10 level and the decline at 12 weeks were independent predictors of SVR.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Medicine, General & Internal
Jur-Shan Cheng, Yu-Sheng Lin, Jing-Hong Hu, Ming-Yu Chang, Hsin-Ping Ku, Rong-Nan Chien, Ming-Ling Chang
Summary: The study found that HCV infection, age, comorbidities, and gender are associated with rheumatic diseases. Untreated patients had a higher mortality rate.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
John B. Whitfield, Tae-Hwi Schwantes-An, Rebecca Darlay, Guruprasad P. Aithal, Stephen R. Atkinson, Ramon Bataller, Greg Botwin, Naga P. Chalasani, Heather J. Cordell, Ann K. Daly, Christopher P. Day, Florian Eyer, Tatiana Foroud, Dermot Gleeson, David Goldman, Paul S. Haber, Jean-Marc Jacquet, Tiebing Liang, Suthat Liangpunsakul, Steven Masson, Philippe Mathurin, Romain Moirand, Andrew McQuillin, Christophe Moreno, Marsha Y. Morgan, Sebastian Mueller, Beat Muellhaupt, Laura E. Nagy, Pierre Nahon, Bertrand Nalpas, Sylvie Naveau, Pascal Perney, Munir Pirmohamed, Helmut K. Seitz, Michael Soyka, Felix Stickel, Andrew Thompson, Mark R. Thursz, Eric Trepo, Timothy R. Morgan, Devanshi Seth
Summary: This study developed a genetic risk score that can identify individuals at high risk of developing cirrhosis. It was found that the risk of cirrhosis is increased over 10-fold in patients with diabetes and a high genetic risk score. This risk assessment could lead to early and personalized management of the disease in high-risk patients.
JOURNAL OF HEPATOLOGY
(2022)
Article
Oncology
Thomas Yau, Joong-Won Park, Richard S. Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro
Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.
Article
Gastroenterology & Hepatology
Isabelle Ollivier-Hourmand, Yohann Repesse, Pierre Nahon, Cendrine Chaffaut, Thong Dao, Thi Thu Nga Nguyen, Patrick Marcellin, Dominique Roulot, Victor De Ledinghen, Stanislas Pol, Dominique Guyader, Isabelle Archambeaud, Fabien Zoulim, Frederic Oberti, Albert Tran, Jean-Pierre Bronowicki, Louis D'Alteroche, Denis Ouzan, Jean-Marie Peron, Jean-Pierre Zarski, Marc Bourliere, Dominique Larrey, Alexandre Louvet, Paul Cales, Armand Abergel, Philippe Mathurin, Ariane Mallat, Jean-Frederic Blanc, Eric Nguyen-Khac, Ghassan Riachi, Laurent Alric, Lawrence Serfaty, Teresa Antonini, Christophe Moreno, Pierre Attali, Dominique Thabut, Christophe Pilette, Jean-Didier Grange, Christine Silvain, Nicolas Carbonell, Brigitte Bernard-Chabert, Odile Goria, Claire Wartelle, Romain Moirand, Christos Christidis, Gabriel Perlemuter, Violaine Ozenne, Jean Henrion, Sophie Hillaire, Vincent Di Martino, Xavier Amiot, Angela Sutton, Nathalie Barget, Sylvie Chevret, Nathalie Ganne-Carrie
Summary: The study indicates that non-O blood type does not influence the disease outcome, disease progression, or overall survival in Child-Pugh A cirrhotic patients.
LIVER INTERNATIONAL
(2022)
Letter
Gastroenterology & Hepatology
Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jerome Boursier, Philippe Mathurin, Celine Ribet, Victor de Ledinghen, Marie Zins, Marie-Aline Charles
Review
Gastroenterology & Hepatology
Line Carolle Ntandja Wandji, Massih Ningarhari, Guillaume Lassailly, Sebastien Dharancy, Emmanuel Boleslawski, Philippe Mathurin, Alexandre Louvet
Summary: Alcohol-related liver disease (ARLD) is a leading cause of chronic liver disease and the prevalence of alcohol-related cirrhosis is increasing worldwide. ARLD is a major indication for liver transplantation (LT), with outcomes similar to other indications. However, questions remain regarding LT for ARLD due to organ shortages. Many centers still require 6 months of abstinence from alcohol before LT, despite evidence showing the poor prognostic value of this criterion. The focus should be on selecting patients who will benefit from LT for ARLD.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Daniel Q. Huang, Philippe Mathurin, Helena Cortez-Pinto, Rohit Loomba
Summary: Global alcohol consumption has increased, leading to a rise in the incidence of alcohol-associated cirrhosis and hepatocellular carcinoma. Heavy alcohol consumption is a major cause of morbidity and mortality. Measures are needed to reduce the burden of alcohol-related liver diseases.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Alexandre Louvet, Valerie Bourcier, Isabelle Archambeaud, Louis d'Alteroche, Cendrine Chaffaut, Frederic Oberti, Christophe Moreno, Dominique Roulot, Thong Dao, Romain Moirand, Jean-Charles Duclos-Vallee, Odile Goria, Eric Nguyen-Khac, Stanislas Pol, Nicolas Carbonell, Jerome Gournay, Laure Elkrief, Isabelle Fouchard-Hubert, Sylvie Chevret, Nathalie Ganne-Carrie
Summary: This study aims to investigate the factors influencing the long-term prognosis of patients with alcohol-related cirrhosis. The results showed that alcohol recurrence and moderate alcohol consumption were associated with poor outcomes. It is recommended that patients with alcohol-related cirrhosis should completely abstain from drinking alcohol.
JOURNAL OF HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Dominique Thabut, Charlotte Bouzbib, Lucy Meunier, Manon Haas, Nicolas Weiss, Alexandre Louvet, Francois Imbert-Bismut, Fanny Mochel, Yann Nadjar, Antoine Santiago, Thierry Thevenot, Veronique Duhalde, Frederic Oberti, Claire Francoz, Audrey Coilly, Marie-Noelle Hilleret, Pascal Lebray, Amelie Liou-Schischmanoff, Louise Barbier, Christophe Duvoux, Georges-Philippe Pageaux, Michael Bismuth, Damien Galanaud, Thomas De Broucker, Jean-Francois Cadranel, Vincent Leroy, Vincent Di Martino, Dominique Larrey, Christophe Camus, Olivier Scatton, Victor De Ledinghen, Ariane Mallat, Marika Rudler, Christophe Bureau
Summary: Hepatic encephalopathy (HE) is a frequent and severe complication of liver disease that often goes undiagnosed due to a lack of understanding and consensus on diagnosis. Non-specific symptoms and comorbidities in cirrhotic patients make differential diagnosis challenging. Guidelines are provided to assist clinicians in diagnosing and treating HE. Liver transplantation may be indicated for HE, but its reversibility post-transplantation and the consequences in patients with other neurological disorders remain controversial.
LIVER INTERNATIONAL
(2023)
Letter
Gastroenterology & Hepatology
Florent Artru, Alexandre Louvet
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Florent Artru, Sophie-Caroline Sacleux, Jose Ursic-Bedoya, Georges-Philippe Pageaux, Alexandre Louvet, Faouzi Saliba
LIVER TRANSPLANTATION
(2023)
Review
Gastroenterology & Hepatology
Luis Antonio Diaz, Juan Pablo Arab, Alexandre Louvet, Ramon Bataller, Marco Arrese
Summary: In this Review, Arrese and colleagues discuss the pathophysiology, clinical management, and future research directions of nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), which are the leading causes of chronic liver disease worldwide. The authors highlight the shared features and interactions between alcohol and metabolic dysfunction in the development and progression of liver disease, as well as the under-reporting of alcohol consumption in patients classified as having NAFLD. They propose the evaluation of both metabolic syndrome and alcohol consumption in patients with fatty liver disease to improve prognosis and personalize treatment.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Massih Ningarhari, Abbas Mourad, Claire Delacote, Line-Carolle Ntandja-Wandji, Guillaume Lassailly, Alexandre Louvet, Sebastien Dharancy, Philippe Mathurin, Sylvie Deuffic-Burban
Meeting Abstract
Gastroenterology & Hepatology
Claire Delacote, Line-Carolle Ntandja-Wandji, Alexandre Louvet, Pierre Bauvin, Guillaume Lassailly, Massih Ningarhari, Sebastien Dharancy, Amelie Bruandet, Guillaume Clement, Xavier Lenne, Philippe Mathurin, Sylvie Deuffic-Burban
Article
Surgery
Kate Minoux, Guillaume Lassailly, Massih Ningarhari, Henri Lubret, Medhi El Amrani, Valerie Canva, Stephanie Truant, Philippe Mathurin, Alexandre Louvet, Gilles Lebuffe, Odile Goria, Eric Nguyen-Khac, Emmanuel Boleslawski, Sebastien Dharancy
Summary: This study investigated the trajectory of HCC patients awaiting liver transplantation who were treated with sorafenib. The results suggest that patients treated for HCC progression have high dropout rates and low survival rates, while patients treated for impossibility of loco-regional therapy have acceptable survival rates.
TRANSPLANT INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Massih Ningarhari, Abbas Mourad, Claire Delacote, Line-Carolle Ntandja Wandji, Guillaume Lassailly, Alexandre Louvet, Sebastien Dharancy, Philippe Mathurin, Sylvie Deuffic-Burban
Summary: This study evaluates the effects of hepatocellular carcinoma (HCC) screening on case fatality rates (CFRs) and cancer-specific mortality in patients with cirrhosis using a modeling approach. The results indicate that six-month ultrasound (US) screening can reduce the 10-year HCC-CFR, and shorter US intervals or the use of MRI can further decrease HCC-related mortality and overall mortality.
HEPATOLOGY COMMUNICATIONS
(2022)